Nucl Med Mol Imaging.  2019 Feb;53(1):35-37. 10.1007/s13139-018-0563-4.

Activities for the Development of Targeted Radionuclide Therapy in Japan

Affiliations
  • 1Department of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan. kinuya@med.kanazawa-u.ac.jp

Abstract

Targeted radionuclide therapy (TRT) is unique because of its efficacy and its theranostic feature in the era of precision medicine. So far, introduction of new TRT has not been going well in Japan due to several reasons including strict regulations, shortage of facilities for TRT, and insufficient reimbursement for TRT in clinic. Japanese community had several strategies to develop TRT in these 10 years, including the establishment of the National Conference for Nuclear Medicine Theranostics in which physicians, scientists, patients, people supporting patients, and industrial people gather. To promote TRTwith supports from the government, the preparatory committee for the establishment of Japan Foundation of Medical Isotope Development (JAFMID) was launched. I would like to call TRT "Precision Nuclear Medicine." When we can add genomic information here, we can put it to new stage of cancer therapy. It is time for us.

Keyword

Targeted radionuclide therapy; Theranostics; Japan; Governmental support

MeSH Terms

Asian Continental Ancestry Group
Humans
Japan*
Nuclear Medicine
Precision Medicine
Social Control, Formal
Theranostic Nanomedicine
Full Text Links
  • NMMI
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr